[article] 
inJournal of Autism and Developmental Disorders > 43-3 (March 2013) . - p.739-746

Titre :	Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials
Type de document :	Texte imprimé et/ou numérique
Auteurs :	Lawrence SCAHILL, Auteur ; Victoria HALLETT, Auteur ; Michael G. AMAN, Auteur ; Christopher J. MCDOUGLE, Auteur ; L. Eugene ARNOLD, Auteur ; James T. MCCRACKEN, Auteur ; Elaine TIERNEY, Auteur ; Yanhong DENG, Auteur ; James DZIURA, Auteur ; Benedetto VITIELLO, Auteur
Article en page(s) :	p.739-746
Langues :	Anglais (eng)
Mots-clés :	Social disability  Autism  Research Units on Pediatric Psychopharmacology (RUPP)  Autism Network  Social withdrawal  Risperidone  Aberrant Behavior Checklist
Index. décimale :	PER Périodiques
Résumé :	There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. Study 2 included 49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training. After 8 weeks of treatment, all active treatments were superior to placebo (effect sizes ranging from 0.42 to 0.65). The findings suggest that the Social Withdrawal subscale may be a useful measure of social disability in acute treatment trials.
En ligne :	http://dx.doi.org/10.1007/s10803-012-1689-3
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=192

[article] Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials [Texte imprimé et/ou numérique] / Lawrence SCAHILL, Auteur ; Victoria HALLETT, Auteur ; Michael G. AMAN, Auteur ; Christopher J. MCDOUGLE, Auteur ; L. Eugene ARNOLD, Auteur ; James T. MCCRACKEN, Auteur ; Elaine TIERNEY, Auteur ; Yanhong DENG, Auteur ; James DZIURA, Auteur ; Benedetto VITIELLO, Auteur . - p.739-746.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 43-3 (March 2013) . - p.739-746

Mots-clés :	Social disability  Autism  Research Units on Pediatric Psychopharmacology (RUPP)  Autism Network  Social withdrawal  Risperidone  Aberrant Behavior Checklist
Index. décimale :	PER Périodiques
Résumé :	There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. Study 2 included 49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training. After 8 weeks of treatment, all active treatments were superior to placebo (effect sizes ranging from 0.42 to 0.65). The findings suggest that the Social Withdrawal subscale may be a useful measure of social disability in acute treatment trials.
En ligne :	http://dx.doi.org/10.1007/s10803-012-1689-3
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=192